No Detail Found!

Clinical effects of TP-based hyperthermic intraperitoneal chemotherapy (HIPEC) on CD133 and HE4 expression in advanced epithelial ovarian cancer

Author(s)
Xianhui Su Department of Pathogenic Biology, Medical College of Hebei Engineering University, Handan 056038, Hebei, China; Department of Pharmacology, Medical College of Hebei Engineering University, Handan 056038, Hebei, China.
Xuewen Sun Department of Pathogenic Biology, Medical College of Hebei Engineering University, Handan 056038, Hebei, China.
Ying Wang Department of Breast Surgery, Affiliated Hospital of Hebei Engineering University, Handan 056029, Hebei, China; Department of Pharmacology, Medical College of Hebei Engineering University, Handan 056038, Hebei, China.
Yanhui Kang Department of Breast Surgery, Affiliated Hospital of Hebei Engineering University, Handan 056029, Hebei, China.
Yuna Dai Department of Breast Surgery, Affiliated Hospital of Hebei Engineering University, Handan 056029, Hebei, China; Department of Pharmacology, Medical College of Hebei Engineering University, Handan 056038, Hebei, China.
Abstract
Objectives: To investigate the clinical effects of TP-based hyperthermic intraperitoneal chemotherapy (HIPEC) on the levels of antigen cluster protein 133 (CD133) and human epididymal secretory protein 4 (HE4) in patients with advanced epithelial ovarian cancer (EOC). Methods: A total of 104 patients with advanced EOC hospitalized in Affiliated Hospital of Hebei Engineering University from April 2015 to December 2018 were assigned to two groups using a random number table. A control group (n =52) treated by the conventional postoperative TP regimen and an observation group (n =52) receiving HIPEC in addition to the conventional postoperative TP regimen. CD133 and HE4 expression in serum, overall response rate (ORR), long-term efficacy, and incidence of drug toxicity were measured for comparative analysis. Results: The serum levels of CD133 and HE4 expression in the observation group were lower than in the control group (P 0.05). Conclusions: TP-based HIPEC can effectively inhibit CD133 and HE4 expression in advanced EOC, which thereby improves the clinical efficacy and encourages longer survival.
Publication Details
Page(s) 1508-1513
DOI DOI not available
Published Journal: Pakistan Journal of Medical Sciences, Volume: 38, Issue: 6, Year: 2022

Request the full text from PASTIC

Keywords
Intraperitoneal chemotherapy, Human epididymal secretory protein 4 (HE4), Antigen cluster protein 133 (CD133), Advanced epithelial ovarian cancer, TP regimen
0

Citations

0

Downloads

98

Views